Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Post-Hematopoietic Stem Cell Transplantation Minimal Residual Disease and Early Relapses in MDS and AML Evolving from MDS

Moreno Festuccia, MD, Kelsey Baker, Theodore A Gooley, PhD, Brenda M. Sandmaier, MD, Joachim Deeg, MD, Brent L Wood, MD PhD, Min Fang, MD PhD, Bart Lee Scott, MD

Blood (2015) 126 (23): 2019.

https://doi.org/10.1182/blood.V126.23.2019.2019

Published: 2015

Journal Articles

Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)

H. Joachim Deeg, M.D., Bart Lee Scott, MD, Frederick R. Appelbaum, MD, Ted Gooley

Blood (2011) 118 (21): 666.

https://doi.org/10.1182/blood.V118.21.666.666

Published: 2011

Journal Articles

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Pamela S Becker, MD, PhD, Bruno C. Medeiros, MD, Frederick R. Appelbaum, MD, Bart Lee Scott, MD, Paul C. Hendrie, MD, PhD, Barry Storer, PhD, Sherry Pierce, RN, BS, Stephen H. Petersdorf, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 3617.

https://doi.org/10.1182/blood.V118.21.3617.3617

Published: 2011

Journal Articles

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Jack M. Lionberger, MD, PhD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Carol Dean, RN, Nathan Holm, BS, Bart Lee Scott, MD, J. Kyle Wathen, PhD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 1552.

https://doi.org/10.1182/blood.V118.21.1552.1552

Published: 2011

Journal Articles

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

Jennifer Vaughn, MD, MSPH, Barry Storer, PhD, Marco Mielcarek, MD, Edus H. Warren, III, MD, PhD, Paul J. Martin, MD, Brenda M. Sandmaier, MD, Elihu H. Estey, MD, Rainer Storb, MD, H. Joachim Deeg, MD, Bart Lee Scott, MD

Blood (2010) 116 (21): 1288.

https://doi.org/10.1182/blood.V116.21.1288.1288

Published: 2010

Journal Articles

Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

Uwe Platzbecker, Johannes Schetelig, Juergen Finke, Rudolf Trenschel, Bart Lee Scott, Guido Kobbe, Kerstin Schaefer-Eckhart, Martin Bornhäuser, Raphael Itzykson, Ulrich Germing, Dietrich Beelen, Gerhard Ehninger, Pierre Fenaux, MD, PhD, H. Joachim Deeg, Lionel Ades

Blood (2010) 116 (21): 3500.

https://doi.org/10.1182/blood.V116.21.3500.3500

Published: 2010

Journal Articles

Induction of Micro RNA-143 and 145 In Pre-Treatment CD34+ Cells From Patients with Myelodysplastic Syndrome (MDS) After In Vitro exposure to Lenalidomide Correlates with Clinical Response In Patients Harboring the Del5q Abnormality

Christopher P. Venner, MD, Alan F. List, Thomas J. Nevill, MD, FRCPC, H. Joachim Deeg, Gisela Caceres, Ph.D., Bart Lee Scott, MD, Lubomir Sokol, MD, PhD, Sandy Sung, Aly Karsan, MD, FRCPC

Blood (2010) 116 (21): 123.

https://doi.org/10.1182/blood.V116.21.123.123

Published: 2010

Journal Articles

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

Srdan Verstovsek, MD, PhD, H. Joachim Deeg, Olatoyosi Odenike, MD, Joy Zhu, Hagop Kantarjian, MD, Zeev Estrov, MD, Bart Lee Scott, MD, Deborah A Thomas, MD

Blood (2010) 116 (21): 3082.

https://doi.org/10.1182/blood.V116.21.3082.3082

Published: 2010

Journal Articles

International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis

Bart Lee Scott, MD, Ted A. Gooley, PhD, Michael L. Linenberger, MD, Brenda M. Sandmaier, MD, David Myerson, MD, Thomas Chauncey, MD, Frederick R. Appelbaum, MD, H. Joachim Deeg, MD

Blood (2010) 116 (21): 3085.

https://doi.org/10.1182/blood.V116.21.3085.3085

Published: 2010

Journal Articles

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Eneida R. Nemecek, MD, Mohamed L. Sorror, MD, MS, Kristine C. Doney, MD, Bart Lee Scott, MD, Tibor J. Kovacsovics, MD, Richard Thomas Maziarz, MD, Ann E Woolfrey, MD, Jean Sanders, MD, Paul V. O’Donnell, Katherine Guthrie, PhD, H. Joachim Deeg, MD

Blood (2008) 112 (11): 2994.

https://doi.org/10.1182/blood.V112.11.2994.2994

Published: 2008

NARROW

Post-Hematopoietic Stem Cell Transplantation Minimal Residual Disease and Early Relapses in MDS and AML Evolving from MDS

Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis

Induction of Micro RNA-143 and 145 In Pre-Treatment CD34+ Cells From Patients with Myelodysplastic Syndrome (MDS) After In Vitro exposure to Lenalidomide Correlates with Clinical Response In Patients Harboring the Del5q Abnormality

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis

A Regimen of Treosulfan and Fludarabine Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for High-Risk Hematologic Malignancies Is Associated with Low Treatment-Related Mortality

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only